Showing results (231-240 of 410) with videos related to
Sort By:
Pageof 41
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.Cell|July 1, 2020
Molecular Pathways of Colon Inflammation Induced by Cancer ImmunotherapyAdrienne M Luoma, Shengbao Suo, Hannah L Williams, et al.Nature Medicine|July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanomaAntoni Ribas, Donald Lawrence, Victoria Atkinson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III TrialsDirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.Journal for Immunotherapy of Cancer|March 14, 2015
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré P Fay, Sabina Signoretti, Marcella Callea, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.Cancer Immunology Research|October 29, 2017
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition TherapyHyunju Lee, F Stephen Hodi, Anita Giobbie-Hurder, et al.Nature Materials|July 11, 2022
Mechanical checkpoint regulates monocyte differentiation in fibrotic nichesKyle H Vining, Anna E Marneth, Kwasi Adu-Berchie, et al.Journal for Immunotherapy of Cancer|September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.Pageof 41